References
- GirouardNSoucyNPatient considerations in the management of multiple sclerosis: development and clinical utility of oral agentsPatient Prefer Adherence201110110821448467
- National Multiple Sclerosis Society [webpage on the Internet]Fact sheet: multiple sclerosisNew York, NYNational Multiple Sclerosis Society2012 Available from: http://www.nationalmssociety.org/chapters/mnm/mediacenter/factsheetmultiplesclerosis/index.aspxAccessed October 18, 2012
- TullmanMJOverview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosisAm J Manag Care201319Suppl 2S15S2023544716
- TrisoliniMG [webpage on the Internet]Comparison of multiple sclerosis guidelines underscores need for collaborationRockville, MDAgency for Healthcare Research and Quality2008 [updated December 8, 2008]. Available from: http://guideline.gov/expert/expert-commentary.aspx?id=16443Accessed March 1, 2013
- GoodinDSFrohmanEMGarmanyGPJrDisease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Councit for Clinical Practice GuidelinesNeurology20025816917811805241
- GiovannoniGSouthamEWaubantESystematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherenceMult Scler201218793294622249762
- AgashivalaNWuNAbouzaidSCompliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort studyBMC Neurology20131313810.1186/1471-2377-13-13824093542
- AgashivalaNWuNWuYKimEBoulangerLBrandesDComparison of time to discontinuation among multiple sclerosis patients receiving fingolimod and other first-line disease-modifying treatmentsProceedings of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) CongressOctober 10–13, 2012Lyon, France
- MillerRMHappeLEMeyerKLSpearRJApproaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of US managed care pharmacists and physiciansJ Manag Care Pharm2012181546222235955
- PittockSJWeinshenkerBGNoseworthyJHNot every patient with multiple sclerosis should be treated at time of diagnosisArch Neurol200663461161416606780
- RoachESEarly multiple sclerosis: to treat or not to treat?Arch Neurol200663461916606782
- RomleyJGoldmanDEberMDastaniHKimERaparlaSCost-sharing and initiation of disease-modifying therapy for multiple sclerosisAm J Manag Care201218846046422928761
- SteinbergSCFarisRJChangCFChanATankersleyMAImpact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort studyClin Drug Investig201030289100
- TanHCaiQAgarwalSStephensonJJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdv Ther2011281516121153000
- TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
- TworkSNippertISchererPHaasJPöhlauDKuglerJImmunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis populationCurr Med Res Opin20072361209121517559722
- SpelmanTBergvallNTomicDReal-world comparative effectiveness of fingolimod and interferon/glatiramer therapies in a switch population using propensity-matched data from MSBaseProceedings of the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)October 2–5, 2013Copenhagen, Denmark
- BergvallNMakinCLahozRRelapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database studyPLoS One201492e8847210.1371/journal.pone.008847224516663
- BergvallNMakinCLahozRComparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysisCurr Med Res Opin201329121647165624059944